Bernstein SocGen cuts Nike stock price target on near-term sales outlook

Bernstein and SocGen cut Nike’s price targets (Bernstein to $72 from $80) despite an Outperform stance as the stock trades near a 52-week low ($41.05, -43% YoY). Near-term fiscal 2027 is flagged for modest revenue declines with heavy promotion controls and margin inflection expected before sales, while optimism returns into calendar 2027 as the transformation program sunsets by end-2026. Nike’s latest results still beat (adj. EPS $0.20 vs $0.12, revenue $11.0B vs $10.85B), but guidance/outlook remains cautious and the outlook reaction is pressured after-hours, with a one-time tariff recovery benefit cited.

Analysis

The market mechanism here is not “turnaround equals upside,” but “margin first, revenue later” — and that usually keeps the multiple capped until investors see at least one clean quarter of full-price sell-through. In the near term, NKE can still look optically cheap, but if top-line declines persist through calendar 2026, cost discipline simply softens the EPS hit rather than creating a true rerating; that is classic value-trap territory.

Second-order effects matter more than the company narrative. Pulling back promotions and low-quality wholesale can support gross margin, but it also hands shelf space and mindshare to share-takers in running and training, especially premium specialists with cleaner product cadence. The likely beneficiaries are the brands that can absorb incremental demand without needing discount support; the losers are wholesale partners and weaker athletic retailers that relied on Nike traffic to clear product.

The November investor day is the real catalyst, because it can either validate a 2027 inflection or expose that the “sunset” of the transformation program is just accounting relief, not demand recovery. Consensus seems to be extrapolating a fiscal 2028 normalization before the sell-through data proves the brand can grow without promotion; if holiday and spring orders do not reaccelerate, the stock can stay range-bound despite any margin beats. A clean falsifier would be evidence that inventory days, full-price mix, and international revenue are all improving simultaneously by year-end.

Key Decisions for Investors

• Do not chase NKE long here; wait for the November investor day and require proof of full-price sell-through plus stable or rising gross margin before adding exposure. Time horizon: 1-3 months for confirmation, 6-18 months for a true rerating.
• For tactical downside protection, buy NKE 3-6 month put spreads on any strength into the investor-day setup; the best reward/risk is if the market continues to question revenue quality while the stock is still below its prior support zone.
• Relative-value idea: long ONON or DECK vs short NKE if you want to express the thesis that share is migrating to faster-moving premium running brands while Nike is still in reset mode. Use this only if channel checks confirm Nike’s wholesale presence is still being reduced.
• If already long NKE, hedge with a small short in XLY or a consumer discretionary ETF rather than trimming the core position outright; this preserves upside if the 2027 thesis is real while reducing beta to a weak consumer tape.
• Set a hard watch item on next-quarter revenue and gross-margin mix: if management cannot show margin expansion alongside narrowing sales declines by the next print, the turnaround window shifts out again and the stock likely remains dead money.